Synlogic Operating Company, Inc.
21Patents
21Active
21Granted
48Portfolio score
Filing activity: Mar 2, 2016 → Aug 9, 2023
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10273489B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | Emerging Cross-Sectional Technologies | 12 | Active |
| US10933102B2 | Bacteria engineered to treat a disease or disorder | Emerging Cross-Sectional Technologies | 7 | Active |
| US11291693B2 | Bacteria engineered to treat metabolic diseases | Emerging Cross-Sectional Technologies | 6 | Active |
| US11471494B2 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | Emerging Cross-Sectional Technologies | 6 | Active |
| US10610546B2 | Bacteria engineered to reduce hyperphenylalaninemia | Emerging Cross-Sectional Technologies | 4 | Active |
| US11723932B2 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | Chemistry; Metallurgy | 4 | Active |
| US11060073B2 | Bacteria engineered to treat diseases associated with hyperammonemia | Chemistry; Metallurgy | 4 | Active |
| US10195234B2 | Bacteria engineered to reduce hyperphenylalaninemia | Emerging Cross-Sectional Technologies | 4 | Active |
| US11766463B2 | Microorganisms engineered to reduce hyperphenylalaninemia | Chemistry; Metallurgy | 2 | Active |
| US11618894B2 | Bacteria engineered to reduce hyperphenylalaninemia | Emerging Cross-Sectional Technologies | 2 | Active |
| US11879123B2 | Bacteria for the treatment of disorders | Emerging Cross-Sectional Technologies | 2 | Active |
| US12171790B2 | Microorganisms engineered to reduce hyperphenylalaninemia | Chemistry; Metallurgy | 1 | Active |
| US11859189B2 | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11685925B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | Emerging Cross-Sectional Technologies | 0 | Active |
| US11384359B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | Emerging Cross-Sectional Technologies | 0 | Active |
| US11883439B2 | Bacteria engineered to treat a disease or disorder | Emerging Cross-Sectional Technologies | 0 | Active |
| US11439673B2 | Bacteria engineered to treat liver disease | Human Necessities | 0 | Active |
| US11845964B2 | Bacteria engineered to treat diseases associated with hyperammonemia | Chemistry; Metallurgy | 0 | Active |
| US11896627B2 | Bacteria engineered to treat metabolic diseases | Emerging Cross-Sectional Technologies | 0 | Active |
| US12409195B2 | Bacteria engineered to reduce hyperphenylalaninemia | Emerging Cross-Sectional Technologies | 0 | Active |
| US11273184B2 | Bacteria engineered to treat disorders in which oxalate is detrimental | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.